Table 1 Statistical analysis of early phase GSTA2 protein with clinical and experimental variables of HCC recipients.
Variables | Early phase GSTA2 | P value |
|---|---|---|
Pretransplantation | ||
Sex | ||
Male (N = 88) | 486.6 (183.9–718.4) | 0.160 |
Female (N = 18) | 436.7 (160.9–941.1) | |
Age | ||
≤57 | 484.3 (230.0 – 941.1) | 0.493 |
>57 | 478.5 (160.9 – 667.8) | |
HbsAg before LT | ||
Positive (N = 85) | 486.3 (160.9–941.1) | 0.252 |
Negative (N = 21) | 455.6 (230.0–667.8) | |
Milan criteria | ||
Within (N = 59) | 477.8 (160.9–718.4) | 0.233 |
Beyond (N = 47) | 496.9 (183.9–941.1) | |
UCSF criteria | ||
Within (N = 74) | 470.2 (160.9–718.4) | 0.173 |
Beyond (N = 32) | 499.1 (183.9–941.1) | |
AFP level before LT | ||
≤400 ng/ml (N = 89) | 477.0 (160.9–941.1) | 0.615 |
>400 ng/ml (N = 17) | 496.9 (242.0–632.2) | |
Type of graft | ||
Live graft (N = 81) | 477.0 (160.9–718.4) | 0.529 |
Cadaveric graft (N = 25) | 501.4 (256.5–941.1) | |
Graft weight to recipient ESLV (%) | R = 0.113 | 0.248 |
Pre–LT AST (μ/l, N = 106) | R = 0.127 | 0.195 |
Pre-LT ALT (μ/l, N = 106) | R = 0.067 | 0.495 |
During and post-transplantation | ||
Cold ischemic time (min) (N = 106) | R = 0.182 | 0.062 |
Warm ischemic time (min (N = 104) | R = 0.218 | 0.026* |
Post-LT ROS level (N = 69) | R = 0.578 | 0.000*** |
Post –LT AST (μ/l, N = 106) | R = 0.268 | 0.022* |
Post-LT ALT (μ/l, N = 106) | R = 0.300 | 0.031* |
Post-LT bilirubin (mg/dl, N = 72) | R = 0.037 | 0.758 |
Post-LT-2 h GM-CSF (N = 100) | R = -0.108 | 0.283 |
Post-LT-2 h IFN-alpha2 (N = 100) | R = 0.060 | 0.550 |
Post-LT-2 h IFN-gamma (N = 100) | R = 0.030 | 0.768 |
Post-LT-2 h IL-10 (N = 100) | R = 0.359 | 0.000*** |
Post-LT-2 h IL-6 (N = 100) | R = 0.052 | 0.606 |
Post-LT-2 h IL-8 (N = 100) | R = 0.306 | 0.002** |
Post-LT-2 h IP-10 (N = 100) | R = 0.120 | 0.234 |
Post-LT-2 h MCP-1 (N = 100) | R = 0.105 | 0.297 |
Post-LT-2 h TNF-alpha (N = 100) | R = 0.026 | 0.795 |
